IPSC

#3144
Century Therapeutics, Inc. - Common Stock
2.0 3 USD
-0.09%
Market Price
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
2.03
2.03
Faixa anual
0.44
3.03
Mudança diária
-8.97%
Mudança mensal
-6.88%
Mudança em 6 meses
-9.38%
Mudança anual
+314.29%
Fechamento anterior
2.2 3
Open
2.0 3
Mínimo
2.0 3
Máximo
2.0 3
Volume
34
Abrir gráfico completo

Financials

Visão geral Relatórios Estatísticas Documents

2026

Current report, Q3 FY2026
Century Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Century Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Century Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K

Century Therapeutics, Inc. current report, Q2 FY2023

Full document

Century Therapeutics, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Century Therapeutics, Inc. (Nasdaq: IPSC) on April 11, 2023. The filing discloses significant changes to the Company's executive leadership and Board of Directors effective April 11, 2023.

Key Financial Metrics

This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate governance and executive compensation adjustments.

Material Changes

  • Departure of CEO: Osvaldo Flores, Ph.D., resigned as President, Chief Executive Officer, and Board member effective April 11, 2023. The Board size was reduced to seven members. The Company stated there was no disagreement regarding operations or policies.
  • Appointment of Interim CEO: Gregory Russotti, Ph.D., formerly Chief Technology Officer, was appointed Interim President and Chief Executive Officer.
  • Appointment of CFO: Michael Diem, Ph.D., formerly Chief Business Officer, was promoted to Chief Financial Officer.

Management Commentary, Compensation, and Risks

Interim CEO Compensation (Gregory Russotti):

  • Base Salary: Increased to $614,092.50 annually.
  • Bonus Structure: A blended target cash bonus calculated based on the portion of the year served in the interim role (55% of new base salary) versus the prior role (40% of prior base salary).
  • Equity Grant: Granted a one-time stock option for 318,750 shares at an exercise price of $3.16 per share. Vesting is 25% on the one-year anniversary, with the remaining 75% vesting monthly over 36 months.
  • Term: The interim role continues until a permanent CEO is hired or terminated with ten days' written notice.

CFO Compensation (Michael Diem):

  • The Board has not yet determined compensation changes related to the promotion. Any material changes will be disclosed in a future amendment.

Contingencies: A separation agreement with Dr. Flores is expected to be filed as an exhibit to an amendment of this report.

Investor Verification Checklist

  • Verify the terms of the separation agreement with Dr. Flores once filed as an amendment to this 8-K.
  • Monitor the timeline for the search and appointment of a permanent CEO to assess the duration of interim leadership.
  • Review the upcoming amendment regarding Dr. Diem's compensation package as CFO.
  • Assess the impact of the leadership transition on the Company's ongoing clinical development programs and strategic direction.

Notícias